Loading
institutionsInstitution
Erasmus MC Cancer Institute
Rotterdam's OECI-accredited comprehensive cancer centre, where peptide receptor radionuclide therapy with lutetium-177 was pioneered and Europe's largest screening trials were led.
Also called: Erasmus MCDaniel den HoedErasmus University Medical Center
Overview
Erasmus MC Cancer Institute unites the former Daniel den Hoed cancer clinic with the oncology departments of Erasmus University Medical Center and holds OECI comprehensive cancer centre accreditation. Its nuclear medicine group under Eric Krenning and Dik Kwekkeboom developed somatostatin-receptor imaging and then 177Lu-DOTATATE peptide receptor radionuclide therapy for neuroendocrine tumours, the treatment later validated in NETTER-1 and approved as Lutathera. Erasmus MC epidemiologists coordinated the European Randomized Study of Screening for Prostate Cancer and the NELSON lung screening trial, which showed a mortality reduction from low-dose CT screening. The institute co-founded the Holland Proton Therapy Centre in Delft with LUMC and TU Delft, and is a leading sarcoma, breast and neuro-oncology trial site under Stefan Sleijfer.
Location
Rotterdam, NL
Type
cancer center · Erasmus University Rotterdam
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#45 · 54 points (0 Newsweek + 0 NCI + 54 from 27 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Erasmus MC Cancer Institute, including child institutions. 875 works · 12,592 citations · 90% open access · 13% clinical trials · 4% reviews.
Oncology works per year
1572022
1972023
1882024
2082025
1252026
Most works
- Bas Groot Koerkamp165 works
- Marc G. Besselink146 works
- Olivier R. Busch71 works
- Hjalmar C. van Santvoort70 works
- Casper H.J. van Eijck69 works
- Bert A. Bonsing62 works
- Ignace H. J. T. de Hingh61 works
- Johanna W. Wilmink52 works
- Pieter Job Tanis51 works
- Cornelis Kees Verhoef50 works
Most cited
- Peptide receptor radionuclide therapy
- Cancer screening trials (ERSPC, NELSON)
- Holland Proton Therapy Centre
- Sarcoma
- Neuro-oncology
H.M.W. Verheul
Representative of Erasmus MC Cancer Institute to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
H.M.W. Verheul represents Erasmus MC Cancer Institute in the Organisation of European Cancer Institutes, which lists the centre among its members in The Netherlands.
Harry J. de Koning
Professor of Public Health and Screening Evaluation, Erasmus MC
Cancer screening evaluationLung cancer CT screeningMicrosimulation modelling
Led the NELSON trial, which confirmed CT screening cuts lung cancer deaths in Europe and shaped screening policy.
J. Jan B. van Lanschot
Emeritus Professor of Surgery, Erasmus MC
Oesophageal surgeryNeoadjuvant chemoradiotherapyOrgan preservation
Surgeon who led the CROSS trial, which made chemoradiotherapy before surgery the standard for oesophageal cancer.
Martin J. van den Bent
Professor of Neuro-Oncology, Erasmus MC Cancer Institute
GliomaAnaplastic gliomaChemoradiotherapy
Led the EORTC glioma trials that established chemotherapy for anaplastic gliomas and the value of 1p/19q and IDH status.
Pieter Sonneveld
Professor of Hematology, Erasmus MC Cancer Institute; Chair, European Myeloma Network
Multiple myelomaTransplant-eligible myelomaDaratumumab quadruplets
Led PERSEUS, which established daratumumab-VRd as the standard for transplant-eligible myeloma.
Remi A. Nout
Professor of Radiation Oncology, Erasmus MC, Rotterdam
Endometrial cancer radiotherapyVaginal brachytherapyCervical cancer radiotherapy
Dutch radiation oncologist who was lead author of PORTEC-2, the trial that showed vaginal brachytherapy is as good as pelvic radiotherapy for high-intermediate-risk endometrial cancer, with fewer side effects.
Valery Lemmens
Director, OncoZON (regional oncology network, south-east Netherlands)
Cancer epidemiologyCancer registries and surveillanceRegional cancer networks
Cancer epidemiologist and professor who became Director of OncoZON, the oncology network of ten hospitals in the south-east Netherlands, in August 2026.
Winette T. A. van der Graaf
Professor of Medical Oncology, Netherlands Cancer Institute and Erasmus MC
Soft-tissue sarcomaAdolescent and young adult oncologyTargeted therapy
Led PALETTE, the trial that made pazopanib the first targeted drug for soft-tissue sarcoma.
rctThe Lancet Oncology 202532 citations
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
Together with NORPACT-1 this left the neoadjuvant question for resectable disease open: FOLFIRINOX before surgery is not proven superior to alternatives, and the comparison against upfront surgery with adjuvant modified FOLFIRINOX is what PREOPANC-3 and Alliance A021806 are running.
rctJournal of Clinical Oncology 2020changed practice786 citations
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
The trial that made neoadjuvant treatment standard for borderline resectable disease and opened the still unresolved question for resectable disease, which PREOPANC-2, NORPACT-1, PREOPANC-3 and Alliance A021806 inherited.
rctNew England Journal of Medicine 2001changed practice2,876 citations
Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer (Dutch TME trial)
The modern basis for offering short-course radiotherapy selectively: it buys local control, not survival, so the decision turns on the predicted recurrence risk from MRI against the long-term bowel and sexual morbidity of pelvic irradiation.
Similar pages
- InstitutionInselspital, Bern University Hospital / University Cancer Center Inselspital
Shares Theranostics, Somatostatin receptor 2, Lutetium-177 dotatate, Radioligand therapy (beta emitters).
- Key paperNETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours
Shares Theranostics, Somatostatin receptor 2, Lutetium-177 dotatate, PET/CT.
- TrialPREOPANC-1
Shares PREOPANC-3, PREOPANC-2, Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial, Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.
- InstitutionUppsala University Hospital / Uppsala University
Shares Somatostatin receptor 2, Lutetium-177 dotatate, Radioligand therapy (beta emitters), Proton therapy.
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Theranostics, Somatostatin receptor 2, Lutetium-177 dotatate, Radioligand therapy (beta emitters).
- InstitutionChulabhorn Hospital / Chulabhorn Royal Academy
Shares Theranostics, Lutetium-177 dotatate, PET/CT, Radioligand therapy (beta emitters).
- PersonMarc G. Besselink
Shares PREOPANC-2, Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial, Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
- TechnologySPECT/CT
Shares SPECT & bone scan, PET/CT, CT (computed tomography), Radioligand therapy (beta emitters).
cancers
fronts
technologies
targets
drugs
ApprovedRadioligand therapy (beta)
Lutetium-177 dotatate · Lutathera
companies
institutions
terms
trials
roadmaps
people
key papers
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trialPreoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC TrialPreoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer (Dutch TME trial)